Lite Strategy (LITS) EV to EBIT (2010 - 2026)
Lite Strategy (LITS) posted EV to EBIT of 1.54 for Q1 2026, down 17.07% on a QoQ basis from 1.31 in Q4 2025, and down 172.22% year-over-year from 2.13 in Q1 2025.
Analysis
Lite Strategy (LITS) EV to EBIT (2010 - 2026) Analysis & Trends
Lite Strategy has reported EV to EBIT for 17 years, with the latest figure at 1.54 in Q1 2026.
- On a quarterly basis, EV to EBIT fell 172.22% year-over-year to 1.54 in Q1 2026; TTM through Mar 2026 was 0.57, a 424.96% decrease from a year earlier, with the FY2025 full-year figure at 0.09, up 106.83% from the prior year.
- EV to EBIT was 1.54 for Q1 2026 at Lite Strategy, down from 1.31 in the prior quarter.
- The five-year high for EV to EBIT was 11.53 in Q3 2022, with the low at 23.02 in Q4 2022.
- Average EV to EBIT over 5 years is 1.38, with a median of 2.13 recorded in 2025.
- The largest YoY upside for EV to EBIT was 751.18% in 2022 against a maximum downside of 10009.41% in 2022.
- Over 5 years, EV to EBIT stood at 23.02 in 2022, then jumped by 127.37% to 6.3 in 2023, then slumped by 66.2% to 2.13 in 2024, then plunged by 161.7% to 1.31 in 2025, then slipped by 17.07% to 1.54 in 2026.
- The last three EV to EBIT figures came in at 1.54 (Q1 2026), 1.31 (Q4 2025), and 16.37 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Lite Strategy | 38.03 Mn | 30.49 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -1.54 |
| Dec 31, 2025 | -1.31 |
| Sep 30, 2025 | -16.37 |
| Jun 30, 2025 | 0.54 |
| Mar 31, 2025 | 2.13 |
| Dec 31, 2024 | 2.13 |
| Sep 30, 2024 | 3.34 |
| Jun 30, 2024 | 1.00 |
| Mar 31, 2024 | 8.56 |
| Dec 31, 2023 | 6.30 |
| Sep 30, 2023 | -2.07 |
| Jun 30, 2023 | 5.13 |
| Mar 31, 2023 | 11.26 |
| Dec 31, 2022 | -23.02 |
| Sep 30, 2022 | 11.53 |
| Jun 30, 2022 | 4.45 |
| Mar 31, 2022 | 11.46 |
| Dec 31, 2021 | 0.23 |
| Sep 30, 2021 | -1.77 |
| Jun 30, 2021 | -1.46 |